ArticleBioactive materials2026
Engineered LINC MIR503HG-loaded extracellular vesicles maintain stemness and pluripotency during long-term hiPSCs culture.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The reduction of stemness and pluripotency during the prolonged culture of hiPSCs poses a significant challenge in regenerative medicine. This study identified LINC MIR503HG as a factor involved in maintaining hiPSCs stemness. Consequently, it developed a highly efficient delivery system based on ADSC-EVs, named MIR503HG-EVs, to optimize the culture strategy for hiPSCs. During the extended culture, MIR503HG-EV-treated hiPSCs developed into colonies with more compact morphology, an increased percentage of viable cells, as well as elevated OCT4, SOX2, and NANOG expression. Furthermore, these cells maintained their chromosomal integrity, as no karyotypic anomalies were detected. Mechanistic studies demonstrated that MIR503HG selectively bound AHCTF1 to facilitate the active nucleocytoplasmic transport of MYC mRNA. This resulted in significantly augmented MYC protein production, which activated the stemness regulatory network. Concurrently, MIR503HG-EVs mitigated the decline in differentiation potential of hiPSCs after several passages by modulating the chromatin accessibility of stemness transcription factors and modifying energy metabolism, including glycolysis and oxidative phosphorylation pathways. Moreover, treatment with MIR503HG-EVs significantly enhanced the differentiation efficiency of high-passage hiPSCs into definitive endoderm, pancreatic, and hepatic lineages, thereby achieving a level of proficiency comparable to that of low-passage clones. Overall, this study identified the addition of MIR503HG-EVs as a convenient, efficient, and safe approach for maintaining high-passage hiPSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.